Icosagen Group, an established research-driven organization providing services for the discovery and production of mammalian cell-derived biopharmaceuticals, today announced that it has acquired the LSA® platform from Carterra®, a leading provider of high-throughput antibody screening and characterization .
Carterra, Inc., the world leader in innovative technologies enabling high-throughput biology, and La Jolla Institute for Immunology (LJI), a globally recognized non-profit research organization dedicated to understanding the power of the immune system to promote human health, announced today that LJI has acquired a .
Carterra, Inc., the world leader in innovative technologies enabling high-throughput biology, and La Jolla Institute for Immunology, a globally recognized non-profit research organization dedicated to understanding the power of the immune system to promote human health, announced today that LJI has acquired a Carterra LSA instrument to enhance its antibody screening and characterization work.
COVID-19 Consortium and resulting Science paper validated the Carterra platform as a game-changer in antibody discoverySALT LAKE CITY, Utah & LA JOLLA, Calif. (BUSINESS WIRE) Carterra, Inc., the world leader in innovative technologies enabling high-throughput biology, and La Jolla Institute for Immunology (LJI), a.
Wellcome Centre for Cell-Matrix Research is funding a nanobody screening project leveraging Carterra's platform The University of Manchester, United Kingdom, and Carterra, Inc., the world leader in